120–250 mg/day of kavalactones from a standardized aqueous extract of noble root. Short periods (4–8 weeks). Never extend without supervision.
Approx. 100 cases of severe hepatotoxicity reported through 2010, some with liver failure. Greater risk with ethanolic/acetonic extracts and with prolonged high doses. Aqueous extracts of noble root have a safer profile but the risk is not zero.
See the study (case reports) →Cochrane meta-analysis of 12 RCTs (n=700): significant reduction in HAM-A vs placebo, a magnitude comparable to benzodiazepines in the short term but without dependence. Greater effect from 5 weeks onward.
See the study (Cochrane meta-analysis) →Improves sleep in people with anxiety, without the residual sedation of benzodiazepines. Effect on sleep latency and subjective quality.
View the study (RCT) →⏱ 3 min read
Kava is a ceremonial drink prepared from the root of Piper methysticum, a plant native to the South Pacific islands (Vanuatu, Fiji, Tonga, Samoa), where it has been consumed for millennia as a central part of the social and religious life of local communities; Pacific islanders drink traditionally prepared kava (fresh root ground in cold water) at social gatherings to produce a state of physical relaxation, mental clarity, and social disinhibition that no pharmacological anxiolytic reproduces with the same combination of effects.
The relevant active compounds are the kavalactones, a family of six compounds (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin) that act on GABA receptors, modulate ion channels, and have mild dopamine-antagonist effects; extracts standardized to 30-70 percent kavalactones are the ones used in the European clinical trials with the best results.
The strongest evidence for kava is its anxiolytic effect: several Cochrane meta-analyses have shown efficacy significantly superior to placebo and comparable to benzodiazepines (oxazepam, bromazepam) in the treatment of generalized anxiety disorder, at doses of 200-300 milligrams of kavalactones per day for 4-8 weeks; the subjective effect typically appears in the first week, much faster than with most serotonergic antidepressants.
The great clinical advantage of kava over benzodiazepines is that it does not produce physical dependence, rapid tolerance, or a significant withdrawal syndrome, which makes it (in principle) an attractive alternative for managing chronic anxiety; in practice, its use is severely limited by the liver safety issue discussed below, which led to its withdrawal from the market in several European countries for years.
In insomnia associated with anxiety (when the problem with sleeping is mental rumination or anticipatory restlessness), kava reduces sleep latency and improves the subjective quality of rest without producing the morning sedation typical of pharmacological hypnotics; in traditional recreational use, it produces a state of conscious tranquility that some describe as “the calm of alcohol without the mental clumsiness or the hangover.”
The most important issue limiting the use of kava is its liver safety profile: starting in 2000, cases of severe hepatitis (some requiring transplantation) were reported in association with its consumption, which led to its ban in Germany, the United Kingdom, Canada, and several other countries, with a gradual return to the market in some of them after causality reviews and improvements in standardization.
Subsequent analyses have concluded that the liver risk appears to be related to: ethanolic or acetonic extracts that carry over liver-toxic compounds (traditional aqueous Pacific preparations have a very different safety profile), use of non-traditional parts of the plant (stems and leaves, not just the root), combination with other hepatotoxic agents (alcohol, acetaminophen, drugs), prolonged use at high doses, and possibly uncharacterized individual genetic susceptibility.
If kava use is being considered, reasonable safety principles are: use only traditional aqueous extracts or standardized European pharmaceutical products that have passed modern safety controls, limit use to periods of less than 4-8 weeks with long breaks, do not exceed 250 milligrams of kavalactones per day, and monitor liver transaminases (ALT, AST) periodically during treatment.
It is strictly contraindicated in people with pre-existing liver disease, those taking hepatotoxic drugs (regular acetaminophen, high-dose statins, some antibiotics, antiepileptics), those who drink alcohol frequently, during pregnancy and breastfeeding, and in people with severe psychiatric disorders in whom the anxiolytic effect may precipitate mood episodes; it is best avoided by anyone taking pharmacological anxiolytics or alcohol at the same time because of the risk of additive sedation and synergistic liver damage.
Information, not medical advice. Scientific evidence reflects the quality of the studies.